EMA Authorised: Vargatef (nintedanib) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Vargatef (nintedanib) by Boehringer Ingelheim International GmbH for the treatment of non-small cell lung cancer in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vargatef

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Boehringer Ingelheim International GmbH. Decision date: 04/07/2024